A Phase 3, Multicenter, Randomized, Double-blind, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Transplantation
Latest Information Update: 03 Oct 2021
At a glance
- Drugs Reparixin (Primary)
- Indications Delayed graft function
- Focus Pharmacokinetics; Registrational
- Acronyms REP0211
- Sponsors Dompe Spa
- 04 Feb 2020 Primary endpoint (Area Under the Curve (AUC) for the Serum C-peptide Level During the First 2 Hours of an MMTT (Mixed Meal Tolerance Test), Normalized by the Number of Islet Equivalent (IEQ)/kg) has not been met, as per Results published in the Diabetes Care.
- 04 Feb 2020 Results published in the Diabetes Care
- 06 Sep 2018 Status changed from active, no longer recruiting to completed.